Another study involving 863 luminal HER2-negative premenopausal and 1498 postmenopausal BC patients revealed that PgR expression levels represent a significant prognostic factor for premenopausal luminal/HER2-negative BC, with an optimal PgR cut-off point identified at 20% [34]. The gene discussed is ERBB2; the disease is breast cancer.